Education
About Us
Working with TipRanks
Follow Us
Wayne Pisano Insider Profile
4 Followers
Wayne Pisano, Director at Altimmune, holds 13.50K shares in Altimmune (Ticker: ALT), holds 0.00 shares in Provention Bio (Ticker: PRVB). Most recently, Wayne Pisano Bought ― shares of Altimmune on Jan 09, 2026 for an estimated value of $20.40K.
Profitable Transactions
1 out of 3 Profitable Transactions
Average Return
+229.60%
Average return per transaction
Time Frame
Compare to
Insider Roles
Director
Roles that Wayne Pisano holds in companies
Most Profitable Insider Trade
Stock:
Provention Bio
(PRVB)
(PRVB)
Rating:Informative Buy
Date:Dec 31, 2018 - Dec 31, 2019
Return:+741.80%
The most profitable trade made by Wayne Pisano
Wayne Pisano's Trading History
Altimmune
Jan 09, 2026
Director
Informative Buy
20.40K
$54.67K
Provention Bio
Apr 27, 2023
―
Uninformative Sell
―
$0.00
List of latest transactions for each holding click on a transaction to see Wayne Pisano's performance on stock
You May Also Like
Wayne Pisano insider profile FAQ
What is the percentage of profitable transactions made by Wayne Pisano?
The percentage of profitable transactions made by Wayne Pisano is 33%.
What is the average return per transaction made by Wayne Pisano?
The average return per transaction made by Wayne Pisano is 229.60%.
What stocks does Wayne Pisano hold?
Wayne Pisano holds: ALT, PRVB stocks.
What was Wayne Pisano’s latest transaction?
Wayne Pisano latest transaction was an Informative Buy of $20.40K.
What was Wayne Pisano's most profitable transaction?
Wayne Pisano’s most profitable transaction was an Informative Buy of PRVB stock on December 31, 2018. The return on the trade was 741.80%.
What is Wayne Pisano's role in Altimmune?
Wayne Pisano's role in Altimmune is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.